Belite Bio Statistics
Total Valuation
Belite Bio has a market cap or net worth of $2.13 billion. The enterprise value is $2.05 billion.
| Market Cap | 2.13B |
| Enterprise Value | 2.05B |
Important Dates
The next estimated earnings date is Tuesday, November 12, 2024, after market close.
| Earnings Date | Nov 12, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Belite Bio has 30.61 million shares outstanding. The number of shares has increased by 14.96% in one year.
| Shares Outstanding | 30.61M |
| Shares Change (YoY) | +14.96% |
| Shares Change (QoQ) | +2.18% |
| Owned by Insiders (%) | 2.76% |
| Owned by Institutions (%) | 0.84% |
| Float | 12.67M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 18.62 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 29.67
| Current Ratio | 29.67 |
| Quick Ratio | n/a |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -1,468.60 |
Financial Efficiency
Return on equity (ROE) is -41.44% and return on invested capital (ROIC) is -26.95%.
| Return on Equity (ROE) | -41.44% |
| Return on Assets (ROA) | -25.62% |
| Return on Capital (ROIC) | -26.95% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.76M |
| Employee Count | 20 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, Belite Bio has paid $6,000 in taxes.
| Income Tax | 6,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +78.61% in the last 52 weeks. The beta is -1.60, so Belite Bio's price volatility has been lower than the market average.
| Beta (5Y) | -1.60 |
| 52-Week Price Change | +78.61% |
| 50-Day Moving Average | 53.52 |
| 200-Day Moving Average | 47.26 |
| Relative Strength Index (RSI) | 69.53 |
| Average Volume (20 Days) | 80,207 |
Short Selling Information
| Short Interest | 270,587 |
| Short Previous Month | 273,467 |
| Short % of Shares Out | 2.14% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 6.93 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -36.72M |
| Pretax Income | -31.62M |
| Net Income | -35.29M |
| EBITDA | -36.54M |
| EBIT | -36.72M |
| Earnings Per Share (EPS) | -$1.22 |
Balance Sheet
| Cash & Cash Equivalents | n/a |
| Total Debt | n/a |
| Net Cash | n/a |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 114.59M |
| Book Value Per Share | 3.74 |
| Working Capital | 110.02M |
Cash Flow
| Operating Cash Flow | n/a |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Belite Bio does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -14.96% |
| Shareholder Yield | -14.96% |
| Earnings Yield | -1.65% |
| FCF Yield | n/a |
Analyst Forecast
The average price target for Belite Bio is $59.00, which is -15.36% lower than the current price. The consensus rating is "Strong Buy".
| Price Target | $59.00 |
| Price Target Difference | -15.36% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 4 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |